MiNK Therapeutics, Inc. financial data

Symbol
INKT on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55% % -14%
Return On Equity 62% % -19%
Return On Assets -180% % 4.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,694,155 shares -88%
Common Stock, Shares, Outstanding 3,963,045 shares 15%
Entity Public Float $13,900,000 USD -32%
Common Stock, Value, Issued $46 USD -88%
Weighted Average Number of Shares Outstanding, Basic 4,443,262 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 4,443,262 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,650,337 USD -31%
General and Administrative Expense $5,775,394 USD 1.4%
Operating Income (Loss) $12,439,355 USD 13%
Net Income (Loss) Attributable to Parent $12,355,261 USD 10%
Earnings Per Share, Basic -2 USD/shares 64%
Earnings Per Share, Diluted -2 USD/shares 64%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $14,281,212 USD 126%
Other Assets, Current $55,208 USD -9.7%
Assets, Current $14,534,321 USD 121%
Property, Plant and Equipment, Net $429,344 USD -46%
Assets $14,963,665 USD 103%
Accounts Payable, Current $3,693,115 USD 56%
Accrued Liabilities, Current $1,256,965 USD -52%
Liabilities, Current $13,433,554 USD 82%
Other Liabilities, Noncurrent $0 USD -100%
Accumulated Other Comprehensive Income (Loss), Net of Tax $692,114 USD -2.9%
Retained Earnings (Accumulated Deficit) $154,073,892 USD -8.7%
Stockholders' Equity Attributable to Parent $13,512,982 USD 23%
Liabilities and Equity $14,963,665 USD 103%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,340,876 USD 47%
Net Cash Provided by (Used in) Financing Activities $5,006,896 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 4,600,585 shares -88%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,342,141 USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14,281,212 USD 126%
Interest Paid, Excluding Capitalized Interest, Operating Activities $3,680 USD -28%
Deferred Tax Assets, Valuation Allowance $30,963,000 USD 4.3%
Deferred Tax Assets, Gross $30,963,000 USD 4.3%
Depreciation $50,765 USD -5.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $12,374,537 USD 12%
Property, Plant and Equipment, Gross $1,258,000 USD -13%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Share-based Payment Arrangement, Expense $2,479,000 USD -30%
Interest Expense $110,000 USD 11%